SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-042002
Filing Date
2021-08-12
Accepted
2021-08-12 16:03:59
Documents
47
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0621_tffpharma.htm   iXBRL 10-Q 411871
2 CERTIFICATION f10q0621ex31-1_tffpharma.htm EX-31.1 12365
3 CERTIFICATION f10q0621ex31-2_tffpharma.htm EX-31.2 12447
4 CERTIFICATION f10q0621ex32-1_tffpharma.htm EX-32.1 6082
5 GRAPHIC image_001.jpg GRAPHIC 2982
  Complete submission text file 0001213900-21-042002.txt   2603463

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tffp-20210630.xsd EX-101.SCH 37715
7 XBRL CALCULATION FILE tffp-20210630_cal.xml EX-101.CAL 19970
8 XBRL DEFINITION FILE tffp-20210630_def.xml EX-101.DEF 132335
9 XBRL LABEL FILE tffp-20210630_lab.xml EX-101.LAB 292106
10 XBRL PRESENTATION FILE tffp-20210630_pre.xml EX-101.PRE 143883
11 EXTRACTED XBRL INSTANCE DOCUMENT f10q0621_tffpharma_htm.xml XML 233550
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 211167441
SIC: 2834 Pharmaceutical Preparations